FDA Approves JNJ's TREMFYA Label Expansion for Crohn's Disease

The U.S. Food and Drug Administration expanded the approved use of Johnson & Johnson's (JNJ) TREMFYA to treat adults with moderately to severely active Crohn's disease, the company announced on May 29, 2026. The decision is based on data from the Phase 3 GRAVITI program showing the drug achieved significant clinical remission rates versus placebo. The label expansion introduces a new mechanism of action into a large inflammatory bowel disease market dominated by TNF inhibitors. TREMFYA generated $3.2 billion in global revenue in 2025 for psoriasis and psoriatic arthritis. Analysts project the Crohn's indication could add more than $1 billion in annual sales by 2028, reinforcing the drug's position as a key growth driver for J&J's pharmaceutical portfolio.